North America to Hold the Lion’s Share in the Plasma Therapy Market

Introduction

The plasma therapy market is primarily driven by its integral use in the healthcare industry for treating orthopedic injuries, cosmetic surgeries, and immunodeficiency disorders. Orthopedic injuries such as tendon injuries, rotator cuff, tennis elbow, and hamstring are quickly and effectively healed using plasma therapy.

Several medical conditions, such as erectile dysfunction and facelift surgeries, are treated using platelet-rich plasma therapy. Platelet-rich plasma is derived from blood plasma, consisting enriched platelets, which assists in quick healing of bone and other soft tissues. However, high cost of medical devices used in plasma therapy hampers market growth. Governments across the globe are actively working to develop plasma-derived medicines and organizing blood donation to ensure an adequate supply of blood plasma, further driving the market growth.  For instance, the government of India announced the national policy to access plasma-derived medicinal products for clinical and therapeutic use. 

Key Highlights

• The plasma therapy market was valued at USD 205.15 million in 2019 and is expected to grow with a CAGR of 14.8% on account of increasing demand for plasma therapy and significant untapped therapeutic opportunities in the field of plasma therapy
• The pure platelet rich plasma segment holds the largest market share owing to the effective results of pure PRP therapy and widespread applications in cosmetics, general, cardiovascular surgeries, and wound healing surgeries
• The autologous segment is expected to account for the largest market share during the forecast period owing to its cost-effectiveness and low threat of disease transmission
• North America leads the plasma therapy market as the region possesses well-established healthcare infrastructure, favorable regulatory framework, and government support

Competitive Players

1. BioLife Plasma Services
2. Grifols International S.A.
3. Biotest
4. CSL Ltd.
5. Cambryn Biologics LLC
6. Bio Products Laboratory Ltd.
7. China Biologic Products Inc.
8. Kedrion S.p.A.
9. Octapharma
10. LFB biopharmaceutical

Recent Developments

• In September 2022, Kedrion S.p.A.'s current shareholders, the Marucci family and FSI, and Permira, announced a partnership to acquire and merge Kedrion and Bio Products Laboratory. The collaboration of the two businesses would establish a dominant global force for drugs made from human plasma that are used to treat severe and uncommon conditions.
• In January 2022, The European Union (EU) announced an expansion of the indication for the subcutaneously administered human immunoglobulin cutaquig, according to Octapharma AG. Patients with acquired immune deficiencies would have more flexible treatment options thanks to the expansion.

Segmentation

1. By Type
   1. Pure Platelet-Rich Plasma
   2. Leukocyte-Rich PRP
   3. Pure Platelet-Rich Fibrin
   4. Leukocyte-Rich Fibrin
   5. Plasma Proteins
2. By Source
   1. Autologous
   2. Allogenic
3. By Application
   1. Orthopedic
   2. Chronic Infectious Diseases
   3. Dermatology
   4. Dental
   5. Cardiac Muscle Injury
   6. Nerve Injury
4. By End User
   1. Hospitals & Clinics
   2. Research Institutions